CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
RFAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04129411
NCT04129411N/ACompleted

Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

Mayo Clinic·interventional·Posted Oct 16, 2019·Updated May 20, 2025

In Brief

A clinical study evaluating RFA for Papillary Thyroid Cancer and Papillary Thyroid Microcarcinoma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 16, 2019
Enrollment StartJun 15, 2020
Primary CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.7 years ago

Interventions

RFAdevice

Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.